Merck Sees $31M in Unusual Options Activity Led by a Massive Deep ITM Call Sweep

By TrendSpider Editor

Merck & Company, Inc. is drawing attention in the options market today, with three unusual contracts totaling $31,103,100 in combined premium, headlined by a deep in-the-money call at the $80 strike worth $29,492,500. MRK shares are trading at $141.715, up 0.79% on the session, and sit closer to the

Merck Sees $31M in Unusual Options Activity Led by a Massive Deep ITM Call Sweep

Merck & Company, Inc. is drawing attention in the options market today, with three unusual contracts totaling $31,103,100 in combined premium, headlined by a deep in-the-money call at the $80 strike worth $29,492,500. MRK shares are trading at $141.715, up 0.79% on the session, and sit closer to the top of their 52-week range of $82.035 to $156.9199, suggesting the stock has already staged a significant recovery from its lows. The sheer size and structure of the dominant call contract points to a highly confident directional bet by at least one institutional player.

Key Drivers of the MRK Stock Move

• Main Catalyst: Three unusual options contracts hit the tape today across calls and puts, generating $31,103,100 in total premium. The standout is a call at the $80 strike expiring June 17, 2027, with 4,700 contracts traded against open interest of just 38%, placing it deep in the money and suggesting a fresh, high-conviction position rather than a hedge on existing exposure.
• Bull Case: The $29,492,500 call sweep at the $80 strike is aggressively bullish. With MRK currently at $141.715, this contract is already $61.715 in the money, making it function almost like a leveraged stock position. The long expiry running to June 2027 gives the holder ample time for the thesis to play out, and the outsized premium relative to open interest confirms this is a new institutional commitment to the upside.
• Bear Case: Offsetting the bullish call activity, a put at the $145 strike expiring December 18, 2026 saw 1,700 contracts trade at an open interest ratio of 111%, meaning volume exceeded existing open interest. This contract is in the money with MRK at $141.715, and its relatively near-term expiry suggests at least one trader is positioning for downside or protecting a long position through year end.

The forward setup for MRK is nuanced. The dominant call sweep carries a structure consistent with a LEAPS replacement strategy or a large institutional accumulation disguised as an options trade, both of which would reflect long-term confidence in Merck's trajectory. However, the in-the-money December put with volume exceeding open interest is a notable near-term caution flag, potentially reflecting concern about a specific event on the horizon, such as a pipeline readout or macro headwind, before the end of 2026. The smaller out-of-the-money call at the $150 strike expiring November 20, 2026 adds a third layer, with 700 contracts and $155,400 in premium suggesting a more speculative near-term bet that MRK can push toward the upper end of its 52-week range of $156.9199 within the next several weeks.

MRK Unusual Options Activity

• Contract 1: Call | Strike: $80 | Expiry: June 17, 2027 | Volume: 4,700 | Open Interest: 38% | Status: In the Money | Premium: $29,492,500
• Contract 2: Put | Strike: $145 | Expiry: December 18, 2026 | Volume: 1,700 | Open Interest: 111% | Status: In the Money | Premium: $1,455,200
• Contract 3: Call | Strike: $150 | Expiry: November 20, 2026 | Volume: 700 | Open Interest: 11% | Status: Out of the Money | Premium: $155,400

MRK Seasonality

Late October and November have historically been active periods for large-cap pharmaceutical names as year-end portfolio positioning and fourth-quarter pipeline catalysts drive institutional rebalancing. The clustering of near-term expirations in November and December within today's flow aligns with typical seasonal patterns for options activity in the healthcare sector heading into year end.

MRK Relative Performance

MRK's current price of $141.715 represents a substantial recovery from its 52-week low of $82.035, with the stock now trading within approximately $15 of its 52-week high of $156.9199. Today's 0.79% gain reflects modest outperformance on a session basis, and the stock's positioning near multi-month highs suggests relative strength compared to the broader pharmaceutical peer group, which has faced intermittent pressure from drug pricing policy concerns and pipeline volatility throughout 2026.